Ichosia Biotechnology, Inc. is a Worcester-based company dedicated to revolutionizing transfusion medicine through the development of Erythrosyn, a naturally derived red blood cell. Their innovative approach aims to address the global shortage of donor blood, ensuring a safe and cost-effective solution for healthcare providers and patients in need.
By harnessing genetics, Ichosia Biotechnology has created a method to mass produce Erythrosyn, which can be produced on demand and is universally compatible, reducing the need for extensive testing. This breakthrough technology not only mitigates the risks associated with supply shortages but also offers significant cost savings for patients and healthcare providers.
Generated from the website